Every 424B that Assembly Biosciences, Inc (ASMB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ASMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASMB filings page.
Assembly Biosciences is offering 3,358,602 shares of common stock and pre-funded warrants to purchase up to 415,000 shares. The prospectus supplement sets an offering price of $26.50 per share (pre-funded warrants priced at $26.499), with estimated net proceeds of approximately $93.3 million (before expenses).
Proceeds are planned to fund clinical development of pipeline candidates and for general corporate purposes. The company reported 15,892,353 shares outstanding as of March 31, 2026. The underwriters have a 30-day option to purchase up to 566,040 additional shares.
Assembly Biosciences, Inc. is offering shares of its common stock and/or pre-funded warrants to purchase shares of common stock pursuant to a preliminary prospectus supplement dated May 21, 2026, subject to completion. The pre-funded warrants are exercisable for one share at an exercise price of $0.001 per share.
The company notes an indicated (non‑binding) interest from Gilead Sciences, Inc. to purchase up to a pro rata number of shares. Shares outstanding were 15,892,353 as of March 31, 2026; net tangible book value was approximately $198.6 million (about $12.50 per share) as of that date. The offering proceeds are intended to fund clinical development and for general corporate purposes.
Assembly Biosciences, Inc. is registering up to 6,980,811 shares of common stock for resale by a selling stockholder. The prospectus covers an offering and resale from time to time by Gilead Sciences, Inc. and its permitted transferees, under a shelf registration, and Assembly will not sell any shares itself under this document.
The shares include stock Gilead previously acquired under several purchase agreements, as well as shares issuable upon exercise of related warrants. Because this is a secondary offering, any sale proceeds will go to the selling stockholder, while Assembly will cover registration and related listing expenses.
Assembly is a biotechnology company focused on therapies for serious viral diseases, including clinical‑stage programs in recurrent genital herpes, hepatitis B and delta viruses, and transplant‑related herpesviruses. Its common stock trades on the Nasdaq Global Select Market under the symbol ASMB, and the last reported sale price was $36.73 per share on November 20, 2025. Investors are directed to detailed risk factors incorporated by reference.